Presentation at Jefferies London Healthcare Conference
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA TO PRESENT AT THE JEFFERIES LONDON
HEALTHCARE CONFERENCE
14 November 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced
that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the Jefferies
London Healthcare Conference as follows:
Date:
Time:
Webcast:
Tuesday, 14 November 2023
2:00pm GMT / 9:00am ET (1.00am on 15 November 2023 AEDT)
Click here
A copy of the presentation slides is attached.
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
USA:
Lisa M. Wilson
T: 917-543-9932
E: ir@maynepharma.com
Authorised for release to the ASX by the Chair
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel
pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40- year track
record of innovation and success in developing new oral drug delivery systems. These technologies have been
successfully commercialised in numerous products that continue to be marketed around the world. To learn
more about Mayne Pharma, please visit maynepharma.com.
Mayne Pharma
Group Limited
Jefferies London Healthcare
Conference
November 14, 2023
Shawn Patrick O’Brien, CEO
1
Disclaimer
The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited
Financial Statements and other market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.
Forward looking statements
● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and
contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as
‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’, ‘target’ and ‘may’, and other words of similar meaning. No representation, warranty or assurance (express
or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially
from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under
the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The
factors that may affect the Company’s future performance include, among others: changes in economic conditions, changes in the legal and regulatory
regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities including approval of our products as
well as their decisions on label claims, competitive developments affecting our products, changes in behaviour of major customers, suppliers and
competitors, interruptions to manufacturing or distribution, acquisitions and divestitures, the success of research and development activities and research
collaborations and the Company’s ability to protect its intellectual property.
Other
● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investorrelations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products.
● ABSORICA®, ACZONE®, ANNOVERA®, BIJUVA®, EPIDUO®FORTE, IMVEXXY®, NEXTSTELLIS®, ORACEA®, and VITAMED® are trademarks of third parties.
2
Mayne Pharma at a Glance
Capitalising on commercial opportunities across three attractive business units
Putting the right people, products, and processes in place to address the needs of patients and
drive long-term sustainable growth in each of our three segments
Branded Products (Women’s Health)
Portfolio Products (Dermatology)
Mayne Pharma portfolio can fill 1 in 3 US
Dermatology Retail Rx’s2
Sales team of 47 in continental US
• Proprietary brands
One of the top 2 specialised women’s
health companies in the US1
Sales team of 94 located throughout
the continental US
(RHOFADE®, FABIOR®, SORILUX®, DORYX®, LEXETTE®)
Reproductive Health
• Flagship product NEXTSTELLIS®
• ANNOVERA® and vitaMedMD®
licensed in December 2022
Menopause Management
• BIJUVA® and IMVEXXY®
licensed in December 2022
• Speciality brands
(Cosette, Upsher-Smith, Torrent, GALDERMA,
Sandoz, Encube)
Patients
Process
1. Based on size of US Women’s Health Commercial Operations calling on OB/GYNs
2. IQVIA recent 12-month TRx totals by molecule, October 2023
• 20+ generic dermatologics
International
•
CDMO
•
Australian Products
•
International Products
3
FY23 Performance Highlights
REFOCUSED ON CORE BUSINESS
• Completed sale of Metrics Contract
Services and US Retail Generics for a
combined sale price of US$565m
• Expanded US Women’s Health portfolio
via license of exclusive rights to
commercialise a portfolio of on-market
women’s health products
IMPROVED FINANCIAL PERFORMANCE
& RESET CAPITAL STRUCTURE
• Delivered revenue growth across all
segments 2H vs. 1H FY23
• Positive 2H direct contribution and
operating free cash flow
• Transformed balance sheet – net cash of
$176.2m (vs FY22 net debt $317m)
• Delivered $46.7m special dividend and
commenced on-market buyback up to 10%
of the Company’s issued capital
GREW ALL THREE SEGMENTS
• BPD/Women’s Health – strong revenue
growth following relaunch of NEXTSTELLIS®
and 2H launch of women’s health portfolio
products; significant 2H improvement in
segment gross profit and direct
contribution
• PPD/Dermatology – delivered significant
2H turnaround in revenue and gross profit
as new commercial discipline introduced to
rebase business following poor 1H result
• International – revenue, gross profit and
direct contribution growth delivered in 2H;
commenced business improvement
program to improve plant efficiency and
secure international CDMO growth
4
First Quarter FY2024 Update1
Pivoting to growth
A$million
Q1 FY23
Q4 FY23
Q1 FY24
Chg YoY
Chg QoQ
Total Net Sales
30.0
68.2
92.3
+207%
+35%
Total Gross Margin
16.4
29.5
53.4
+226%
+81%
Gross Profit %
55%
43%
58%
300bp
1500bp
Underlying EBITDA
(31.5)
(18.6)
(0.2)
+94%
+99%
“Cash” EBITDA
(32.1)
(19.5)
(1.7)
+95%
+91%
Dermatology gaining
momentum
•
Net sales of US$26.1M, up
53% on Q4FY23
•
Gross margin recovery
reflecting core portfolio
profitability and new
product launches
Strong total company
results
Women’s Health
fundamentals improving
•
•
All 3 operating segments
delivered positive
contribution margin2 for Q1
Net sales of US$21.1M, up
71% on Q4FY23
•
Net sales up 35% vs Q4FY23
•
NEXTSTELLIS® net selling
price (NSP) restored to prior
levels
•
Gross margin up 81% vs
Q4FY23
•
Initiated a new targeted
cost management program,
removing US$10M of costs
•
Proposed increase to share
buyback program
•
Licensed TXMD products
generating robust returns,
maintaining conservative
gross-to-net (GTN)
1. All Q1 results unaudited
2. Contribution margin calculated as gross margin less direct OPEX – excludes allocation of shared functions & overhead
5
Branded Products Division (BPD) / Women’s Health
Women’s Health / Branded Products Division (BPD)
Leader in U.S. Women’s Health
● A leading position in strong and growing market with four novel women’s healthcare products
● Licensing rights acquisition added a complementary portfolio of stable products with long patent lives to the
Company’s flagship women’s health product, NEXTSTELLIS®
● One of the top 2 specialised women’s health companies in the US1
● Strong commercial infrastructure in place with sales team of 94 able to reach target customers
Reproductive Health
1. Based on size of US Women’s Health Commercial Operations calling on OB/GYNs.
Menopause Management
Prenatal Vitamins
7
Women’s Health / Branded Products Division (BPD)
Q1 FY24 results1
● Quarter on quarter segment net sales +72% for BPD
FY24 Women’s Health
Outlook
● Segment performance reflects growth in expansion portfolio as well
as improved performance of NEXTSTELLIS® following access improvements
(co-pay) and new targeting strategy implemented in December
● Continuing to refine NEXTSTELLIS® marketing strategy: reduction of DTC due
to insufficient ROI and removed 6 non-profitable territories
● Direct OPEX increase vs prior year driven by sales force expansion; but have
eliminated US$8 million in segment costs for fiscal year 24
● Q1FY24 gross margin representative of go-forward profile
US$million
Q1 FY23
Q4 FY23
Q1 FY24
Total Net Sales
4.4
12.7
21.9
Total Gross Margin
3.6
11.5
18.0
Gross Profit %
82%
90%
81%
Direct operating expense
11.9
15.0
15.9
Direct contribution2
(8.3)
(3.5)
2.0
•
Complete integration of
expansion portfolio with a
focus on growth and
improving net selling prices
•
Deliver Rx growth across
all brands
•
NEXTSTELLIS® breakeven
run rate in 1HFY243
•
BIJUVA® half strength
launch Q3 FY24
•
Take advantage of changes
to ACA law
1. All Q1 results unaudited
2. Direct contribution calculated as gross margin less direct OPEX – excludes allocation of shared functions & overhead incl med affairs
3. NEXTSTELLIS® Breakeven is defined as annualised gross margin at exit period less annualised direct opex
8
Weekly NEXTSTELLIS® cycles1 seeing steady growth
● 1Q24 vs 4Q23 unit growth of 9.7%, net revenue +69%, NSP restored to above 1HFY23 level
● Refreshed marketing strategy and Medical Affairs support
● Additional US patent protection to NEXTSTELLIS® granted – expiry 2036
1 - Cycle totals based on IQVIA Exponent Data adjusted for non-reporting pharmacies through 27OCT23
9
Expanded Women’s Health branded portfolio adding significant value
● Cash return of US$24.3 million during nine months of ownership1 or ~24% annualised
● Transaction to date (9 months) assets performing at ~4.2 years simple payback2
● Intellectual property protection 2032 through 2039
● Ongoing optimization of operating efficiencies
● BIJUVA® half strength launch opportunity in the second half of FY24
ANNOVERA®, IMVEXXY®, BIJUVA® & PN-V
US $ Millions
$18.0
$15.9
$16.0
$14.6
$14.0
$12.0
$10.4
$10.0
$8.5
$8.0
$6.0
$4.0
$2.0
$Q4
1. Contribution minus royalties paid or due
2. Purchase price + NWC divided by annualised incremental contribution: US$153M / (US$27.3M*1.33) = 4.2
Q1
Q2
Q3
Calendar Quarters 2022 & 2023
10
Portfolio Products Division (PPD) - Dermatology
Dermatology / Portfolio Products Division (PPD)
Building market leadership and scale
● Five proprietary brands and 20 generic dermatologics
● Recent acquisition of RHOFADE®, an FDA-approved topical cream used to treat rosacea (launched 10/2/2023)
● Mayne Pharma portfolio can fill 1 in 3 US Dermatology Retail Rx’s1
● Market presence as top 10 US products by revenue - gABSORICA® (isotretinoin) capsules, gEPIDUO® FORTE
(adapalene/benzoyl peroxide) gel and gACZONE® (dapsone) gel
● Building on market position with a strong and profitable pipeline of products to meet broader patient needs
● Differentiated channel strategy through specialty pharmacy growth and online platforms like GoodRx
+20 generic
dermatologics
1. IQVIA recent 12-month TRx totals by molecule
12
Dermatology / Portfolio Products Division (PPD)
Q1 FY24 results1
● Q1 FY24 Net Sales +285% vs PCP, +53% vs prior quarter
● Q1 FY24 Gross Margin +224% vs PCP, +302% vs prior quarter
FY24 Dermatology
Outlook
● Net revenues growing steadily, benefitting from improved GTN and NPLs
(DORYX® MPC 60 mg, AG ORACEA®)
● Unique prescriber patient fulfilment process (disintermediation) is active
● Co-pay monitoring expected to deliver improvements beginning Q2 and
continuing throughout the FY
US$million
Q1 FY23
Q4 FY23
Q1 FY24
Total Net Sales
6.8
17.1
26.2
Total Gross Margin
3.7
2.9
11.8
Gross Profit %
54%
17%
45%
Direct operating expense
5.2
3.9
5.3
Direct contribution2
(1.6)
(0.9)
6.6
• Positive profit and
contribution FY24
• Revenue growth via
new/recent product launches
(RHOFADE®, isotretinoin,
generic of ORACEA®, DORYX®
MPC 60 mg)
• Transition unique prescriber
patient fulfilment process from
pilot to fully scaled operation
• Enter into capital light,
accretive business
arrangements and drive
commercial excellence
1. All Q1 results unaudited
2. Direct contribution calculated as gross margin less direct OPEX – excludes allocation of shared functions & overhead incl med affairs
13
Acquisition of global rights to RHOFADE®
Adds to portfolio of products expected to generate positive EBITDA and cash flow in FY24
FDA-approved
topical cream
proven to reduce
persistent facial
redness caused
by rosacea by at
least two grades
In 29-day trials,
patients saw
significant
redness reduction
through 12 hours
Acquired for US$8
million and
launched October
2, 2023
1. IQVIA recent 12-month TRx, NRx and RRx for RHOFADE® Oct 27, 2023
Complementary
to authorised
generic (AG)
ORACEA®
Expands portfolio
with minimal
added expense,
aligning with
overall strategy of
Dermatology
portfolio
Reported
prescription levels
are above
expectation and
demand is
returning to prior
levels1
14
Dermatology Growth
● Net revenues growing steadily, benefitting from improved GTN and NPLs (DORYX® MPC 60
mg, AG ORACEA®)
● Co-pay monitoring expected to deliver improvements beginning Q2 and continuing
throughout the FY
● Unique prescriber patient fulfilment process (disintermediation) is active
15
Using Unique Fulfilment Process to Disintermediate the Pharmaceutical Value Chain
Pharmaceutical Value Chain
The pharmaceutical value chain is filled with
inefficiencies and pain points
Plan Sponsor
• Multiple stakeholders with opposing financial interests cause
inefficiencies, higher costs, lack of transparency, and lack of trust
• PBMs are incentivised by rebates and the top 3 control 80% of
the market, resulting in higher costs to consumers, fewer choices
for prescribers, and margin pressures for manufacturers
Manufacturer
• Purchasing alliances control >95% of the market and
manufacturer bargaining power is limited
HCP/Prescriber
• Consumers face high prices and coverage uncertainty and don’t
trust online offerings which are difficult to navigate
• Prescribers/HCPs seek reduced administrative burden, greater
choice in patient treatment, and simpler patient access to
minimise abandonment and promote adherence
Wholesaler
Pharmacy
Patient
THE GOAL: Help patients receive quality drugs quickly and at the best price while
increasing prescriber efficiency and customer satisfaction.
16
Disintermediation Strategy
Mayne Pharma’s unique platform spans the entire value chain, allowing for the ability to create a
comprehensive, frictionless, transparent, and cost-effective experience
Why Dermatology?
✓ There is great desire for
disintermediation in the industry,
with the Dermatology segment a
logical starting point
✓ Most dermatological conditions are
not permanently cured, resulting in
ongoing demand/continuous refills
✓ Long cycle times for treatment
✓ Conditions are non-acute and
patients are more willing to wait for
shipping and shop online
✓ Insurance coverage is poor and
getting worse
Why Mayne Pharma?
130 territory
representatives
>60% of
prescribing activity
✓ Drug sourcing ability:
• Mayne Pharma portfolio is capable of
filling 1 in 3 US Dermatology Retail Rx(1)
• Access to wholesalers and intermediary
platforms
• Established relationships with Bx & Gx
manufacturers
Manufacturer
✓ Pharmacy network allows for
HCP/Prescriber
consistent product availability,
choice, and pricing:
• Adelaide Apothecary for cash-pay claims,
licensed to operate in 50 states
• 400+ specialty pharmacy locations and
partnerships for reimbursed claims
✓ Extensive provider/customer
Wholesaler
Pharmacy
Patient
coverage:
• 145+ field representatives
• Reach of 50k+ prescribers in targeted
therapeutic areas, covering >60% of
prescribing activity
.
1 IQVIA recent 12-month TRx totals by molecule October 2023
17
International
International
● Q1 FY24 net sales and margin down
quarter on quarter, due to production
timing
● Costs continue to be managed and our
ongoing productivity initiatives are
designed to deliver benchmark
outcomes in pharma manufacturing
● The new business pipeline to drive
large and long run volumes through
our FDA and TGA registered Salisbury
facility is building; focused on
converting these into real
opportunities
● Continued progress in growing Opioid
Substitution Therapy (OST)
opportunities in Europe
FY24 International
Outlook
Mayne
Pharma
Australia
A$million
International
Product
Sales
CDMO
• Pursue targeted
investments and new
manufacturing revenue
streams
Q1 FY23
Q4 FY23
Q1 FY24
Total Net Sales
13.3
23.1
17.9
Total Gross Margin
5.5
7.2
7.1
Gross Profit %
42%
31%
40%
Direct operating expense
2.8
2.9
2.9
Direct contribution1
2.7
4.2
4.2
• Continue to drive
specialty and generic
product sales including
NEXTSTELLIS® in
Australia
• Invest in a targeted
manner in the Salisbury
facility to improve our
productivity and
capabilities
1. Direct contribution calculated as gross margin less direct OPEX – excludes allocation of shared functions & overhead incl med affairs
19
Pivoting to Growth
Strategy for 2024 Growth
Continuing positive momentum into FY24
Women’s Health
Dermatology
International
✓ Deliver positive contribution
margins in all three segments
✓ Return Company to positive
EBITDA and cash generation in
FY24
✓ Optimise cost base with OPEX
reductions of approximately
US$10M
✓ Proposed increase in share
buyback from 10% to 15% (to be
approved at Company’s AGM)
• Complete integration of
licensed portfolio with a
focus on growth and
improving net selling prices
• Deliver Rx growth across all
brands
• NEXTSTELLIS® breakeven
run rate in 1HFY241
• BIJUVA® half strength
launch
• Take advantage of changes
to ACA law
1. Breakeven is defined as gross margin equivalent to direct OPEX on an annualised basis
• New product launches
• Pursue targeted
investments and new
manufacturing revenue
streams
• Transition unique prescriber
patient fulfilment process
from pilot to fully scaled
operation
• Continue to drive specialty
and generic product sales
including with NEXTSTELLIS®
in Australia
• Enter into capital light,
accretive business
arrangements and drive
commercial excellence
• Invest in a targeted manner
in the Salisbury facility to
improve our productivity
and capabilities
• Positive profit and
contribution FY24
21
Capital Management
Q1 Capital update
FY24 Capital Management Priorities
Current company cash balance A$163m Sept 30, 2023
Q1 cash usage (A$57m)
● Maintain conservative balance sheet and solid liquidity
position through transition phase with planned capital
structure review ongoing
Cash uses Q1 FY24 (A$):
● Execute on invested portfolio, no acquisitions planned
Repayment receivable facility
Share repurchase
RHOFADE® transaction
Cash used: Financing & investing
10.7m
1.3m
13.1m
25.1m
Catch-up payments and chargebacks
Seasonality of OPEX
Discontinued operations & legal
Other
Cash used: Operations
14m
7m
8m
3.5m
32.5m
● Improvement in cash conversion cycle (Inventory + AR Q1FY24
reduced A$92M vs pcp)
● Tight management of discontinued business obligations /
provisions
● Improve leverage on fixed assets (PP&E – efficiency and
utilisation Salisbury)
● Accelerate share buy-back:
-
Current 10% limit (1.8M shares bought back, A$6.9m as at 30 Sept)
Propose to increase the buy-back capacity to up to 15% in the next
12 months (resolution to be included in AGM)
Further improvement in profitability & management of discontinued operations expected to deliver
positive operating cash Q2 through Q4
22
Q&A
Mayne Pharma
Group Limited
ASX:MYX
You deserve tomorrow.
23
Appendix – extract from FY23 results presentation
FY23 Group Financial Overview
•
Results are presented from continuing operations to exclude Metrics Contract Services (MCS) which was divested on 4 October 2022 and to
exclude the US Retail Generics business (previously included in the Portfolio Products (PPD) segment) which was divested on 7 April 2023. The
results include adjustments to reflect movements to adjust FY22 results to a comparable basis.
•
Group Revenue up 17% as growth in BPD (NEXTSTELLIS® and contribution from portfolio of women's health products licenced under the exclusive
licencing agreement with TXMD 31 December 2022) and International business exceed decline in PPD (dermatology).
•
Increase of reported Gross Profit is offset by a decline in margin to 45.5% vs 50.1% in FY22 reflecting challenges in PPD (dermatology)
•
Reported EBITDA loss reflects higher operating expenses to support future growth
•
Reported Net Loss after tax includes $215.4m expenses therein $134.7m related to depreciation & amortisation and asset (primarily intangibles)
impairments, $47.7m income tax expense, $28.8m finance expenses primarily discount unwind on earnouts.
A$ million1
FY23
FY22
Change
Reported Revenue
$183.6
$157.1
$26.5
Reported Gross Profit
$83.5
$71.6
$11.9
Reported EBITDA
($102.0)
$9.0
($111.0)
Reported Net Loss After Tax
($317.4)
($220.1)
($97.3)
Underlying EBITDA2
($95.3)
($59.6)
($35.7)
1. Attributable to members. EBITDA excludes asset impairments.
2. Refer to FY22 Results Presentation for adjustments to underlying EBITDA
25
FY23 Segmental Performance
Refocused business delivering improved momentum and positive contribution in 2H
Reported results (A$m)
Revenue
Portfolio Products
Branded Products
International
Total
Operating expenses
- Dermatology
1
- Other
Portfolio Products
Branded Products
International
Total
1HFY23
2HFY23
FY23
FY22
11.1
13.4
27.6
52.1
45.9
48.5
37.1
131.5
57.0
61.9
64.7
183.6
92.2
10.6
54.4
157.1
Gross profit
Portfolio Products
Branded Products
International
Total
14.4
3.1
17.5
36.0
6.1
59.6
13.9
0.1
14.1
45.6
6.0
65.6
28.3
3.3
31.6
81.6
12.1
125.3
23.7
1.5
25.2
55.1
9.6
89.9
Direct Contribution
- Dermatology
- Other
Portfolio Products
Branded Products
International
Total
1. Other within PPD represents Adelaide Apothecary
1HFY23
2HFY23
FY23
FY22
-2.6
10.7
8.8
16.9
13.3
43.2
10.1
66.6
10.7
53.9
18.9
83.5
45.4
8.4
17.7
71.6
-17.0
-3.1
-20.1
-25.4
2.8
-42.7
-0.7
-0.1
-0.9
-2.3
4.1
0.9
-17.7
-3.3
-21.0
-27.6
6.9
-41.8
21.7
-1.5
20.2
-46.6
8.1
-18.3
26
FY23 Group Financial Overview
Consolidated balance sheet
A$ million
FY23
FY22
Change
Cash and equivalents
92.6
96.7
(4.1)
Inventory
82.7
108.9
(26.2)
Receivables
194.9
268.2
(73.3)
PP&E
43.7
218.4
(174.7)
Intangibles & goodwill
617.3
427.5
189.8
Income tax receivable
14.6
14.1
0.5
Right of use assets
7.8
7.5
0.3
Other assets
193.8
146.6
47.2
1,247.4
1,287.9
(40.5)
Payables
246.5
187.6
58.9
Interest-bearing borrowings (inc leases)
47.5
413.7
(366.2)
Other financial liabilities
296.2
126.1
170.1
Other liabilities
22.8
22.3
0.5
Total Liabilities
613.0
749.7
(136.7)
Equity (attributable to members)
634.4
538.2
96.2
AUD:USD FX rate
0.664
.689
Net Cash / (Debt)
172.6
(317.0)
Total assets
● Working capital reductions reflective of
MCS and RGx divestments and
transformation journey of the company.
● Payables reflect increase in GTN
liabilities YoY due to increased derm
GTN profile, increase in returns
provision at H1FY23, growth in WH
revenues.
● Interest bearing borrowings includes:
$10.8m receivables finance facility,
$28.5m convertible notes, and $8.2m
lease liabilities
● Other Financial Liabilities includes
$291.4m earn out and deferred
consideration liabilities relating
to TXMD transaction and
MCS transaction
● Net cash calculation includes
marketable securities held in overnight
deposits
489.6
27
Share your feedback
Discover